←
Guillaume Canaud (MD, PhD)693 posts
Guillaume Canaud (MD, PhD) avatar

Guillaume Canaud (MD, PhD)

@CanaudLab

Translational medicine. Hôpital Necker Enfants Malades/Université Paris Cité. US FDA and EMA approvals of alpelisib for PROS patients thanks to our works

◷ Joined June 2018▧ 67 Photos and videos
Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·Jun 17

A huge thank you to the @eshgsociety for this extraordinary honor. I am deeply grateful and humbled to receive the Mendel Medal. This recognition is not mine alone, it belongs to my entire team, whose outstanding work, dedication, and passion made it possible. Thank you all.

Post attachmentPost attachmentPost attachment
GoPI3Ks (Genetic Overgrowth PI3K Support) avatar
⟳ Guillaume Canaud (MD, PhD) retweeted
GoPI3Ks (Genetic Overgrowth PI3K Support)@GoPI3Ks·May 22

Big news today: Vijoice (Alpelisib) has been approved for use by the EMA. This medication addresses an unmet medical need for patients with severe or life-threatening PIK3CA-related overgrowth spectrum (PROS) disorders ema.europa.eu/en/news/first-…

Public Meducation avatar
⟳ Guillaume Canaud (MD, PhD) retweeted
Public Meducation@PubMeducation·May 22

First Drug for Severe Overgrowth Disorders Approved in Europe! The European Medicines Agency has conditionally authorized the use of Vijoice (aka alpelisib/Novartis) for the treatment of patients with PROS disorders. PROS = PIK3CA-related overgrowth spectrum. A diverse group of rare genetic conditions that are characterized by uncontrolled growth of some tissues. They are caused by a mutation in the PIK3CA gene. Vijoice is indicated for patients over two years of age with severe or life-threatening manifestations of PROS, requiring systemic therapy. Vijoice showed a 20% tumor reduction in about 37.5% of patients. This is a condition that has many unmet medical needs, and this is the first step in the right direction. #PROS #GrowthDisorder #EMA #EuropeanMedicine

Post attachment
Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·May 13

Our latest paper just released. Congratulations to Ilaria, Charles and the entire team 🍾🥳🔥Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disorders academic.oup.com/pnasnexus/a…

Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·Mar 11

What extraordinary news — I’m extremely proud and honored. Thank you @eshgsociety for this very prestigious award, which I share with the entire team. 🎉🍾🥂

The ESHG Award, ELPAG Award and the Mendel Lecturers of the #eshg2026 #hybridconference have talked to Mary Rice. Read the interviews and find out more about their backgrounds: 2026.eshg.org/speakers/speak…

Post attachment
Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·Jan 12

Aujourd’hui nous célébrions les 10 ans d’introduction de l’alpelisib (BYL719) chez Emmanuel, le premier patient PIK3CA traité dans le monde. Immense fierté🇫🇷 10 years on alpelisib for Emmanuel, the first ever PROS patient treated. Fantastic accomplishment for all of us 🎉🥳🍾🥂

Post attachmentPost attachment
Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·22 Nov 2025

Our latest article just released. Congratulations to @IlariaGalasso and @morin_gbrl 🍾🍾🎉🎊Vascular malformations: from genetics to therapeutics | EMBO Molecular Medicine embopress.org/doi/full/10.10…

Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·10 Nov 2025

Our latest review on kidney drug repositioning in @Kidney_Int. Congrats to the 2 outstanding contributors @morin_gbrl and @IsnardPierre1👏🍾🥂Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease kidney-international.org/art…

INEM NECKER avatar
⟳ Guillaume Canaud (MD, PhD) retweeted
INEM NECKER@NeckerInem·10 Jul 2025

#France2030 | Félicitations à Guillaume Canaud @CanaudLab, lauréat d’une Chaire d’excellence en Biologie/Santé pour son projet sur les malformations vasculaires liées à KRAS. 🎯Objectif : développer des thérapies ciblées pour une médecine ultra personnalisée. 👏🏼

📢#France2030 15 nouveaux chercheurs et chercheuses d'exception récompensés pour les « Chaires d’excellence en Biologie / Santé » !🧑‍🔬 Ce dispositif vise à renforcer l’attractivité de la recherche biomédicale française🧪🇫🇷🥼 Pour découvrir les lauréats👉swll.to/ilGDHI

Post attachment
Guillaume Canaud (MD, PhD) avatar
Guillaume Canaud (MD, PhD)@CanaudLab·10 Jul 2025

Excellente nouvelle et merci pour votre soutien! Ce financement devrait accélérer l’identification de nouveaux traitements pour les malformations vasculaires secondaires a des mutations de KRAS 🍾🎊🥳 Wonderful news! This is a great funding for KRAS-vascular malformations! 🙏🙏

📢#France2030 15 nouveaux chercheurs et chercheuses d'exception récompensés pour les « Chaires d’excellence en Biologie / Santé » !🧑‍🔬 Ce dispositif vise à renforcer l’attractivité de la recherche biomédicale française🧪🇫🇷🥼 Pour découvrir les lauréats👉swll.to/ilGDHI

Post attachment